OptimizeRx Co. (NASDAQ:OPRX) – Equities research analysts at B. Riley lifted their Q4 2019 earnings per share (EPS) estimates for shares of OptimizeRx in a report issued on Thursday, May 9th, according to Zacks Investment Research. B. Riley analyst A. D’silva now anticipates that the company will post earnings of $0.13 per share for the quarter, up from their previous estimate of $0.11. B. Riley also issued estimates for OptimizeRx’s FY2020 earnings at $0.52 EPS.
Separately, Zacks Investment Research lowered OptimizeRx from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. OptimizeRx presently has a consensus rating of “Buy” and an average target price of $19.00.
OPRX stock traded down $0.72 during midday trading on Monday, reaching $13.33. 73,445 shares of the stock were exchanged, compared to its average volume of 54,648. The firm has a market capitalization of $186.14 million, a P/E ratio of 266.60, a P/E/G ratio of 1.65 and a beta of 0.50. OptimizeRx has a 52 week low of $7.25 and a 52 week high of $18.39. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.03.
A number of hedge funds have recently bought and sold shares of OPRX. BlackRock Inc. acquired a new position in OptimizeRx during the 4th quarter worth approximately $55,000. Morgan Stanley raised its stake in OptimizeRx by 37.6% during the 1st quarter. Morgan Stanley now owns 8,036 shares of the company’s stock worth $102,000 after buying an additional 2,194 shares during the period. Citigroup Inc. acquired a new position in OptimizeRx during the 1st quarter worth approximately $119,000. Westwood Management Corp IL acquired a new position in OptimizeRx during the 1st quarter worth approximately $127,000. Finally, Wells Fargo & Company MN raised its stake in OptimizeRx by 18.1% during the 1st quarter. Wells Fargo & Company MN now owns 12,382 shares of the company’s stock worth $157,000 after buying an additional 1,898 shares during the period. 48.47% of the stock is currently owned by institutional investors and hedge funds.
In related news, major shareholder Awm Investment Company, Inc. sold 21,397 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $15.05, for a total transaction of $322,024.85. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company’s cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.